Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.
about
Developing stem cell therapies for juvenile and adult-onset Huntington's diseaseThe role of neurotrophins in multiple sclerosis-pathological and clinical implicationsSystemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's diseaseSmall-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's diseaseDifferential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease.Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease.BDNF regulates the expression and distribution of vesicular glutamate transporters in cultured hippocampal neurons.New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases.Astrocyte-Specific Overexpression of Insulin-Like Growth Factor-1 Protects Hippocampal Neurons and Reduces Behavioral Deficits following Traumatic Brain Injury in Mice.Cognitive training modifies disease symptoms in a mouse model of Huntington's diseaseThe group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease miceBDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.Failure of axonal transport induces a spatially coincident increase in astrocyte BDNF prior to synapse loss in a central target.Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.Targeting sirtuin-1 in Huntington's disease: rationale and current status.Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models.Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDPSuppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models.Role of BDNF in central motor structures and motor diseases.Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.The role of growth factors as a therapeutic approach to demyelinating disease.Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms.FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.Pyk2 modulates hippocampal excitatory synapses and contributes to cognitive deficits in a Huntington's disease model.Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
P2860
Q26799722-D5A6DFED-891D-453F-B5C1-B32044221BC7Q26849274-A6D2D24F-80AE-4ACA-A057-E9F01CA969BFQ28488296-AA83AABD-8622-42F6-B3AE-81E60BD9139EQ34330172-EA75C930-70C3-407D-9997-95CB65A034EEQ34341619-330A7661-4C6C-423E-BA5C-5866411AA760Q34406937-E5B14E33-916F-4DEB-B404-F6C0E4B74381Q34551784-508AD75A-DDC4-46DF-9674-21C1FF009637Q34567939-83709F4F-4D2A-44B0-96BF-5C6122244A5EQ34796693-D913FF7A-517E-4D0D-B95E-2F54625A878CQ36013200-5A917013-8F7F-441F-81C5-9981DA33E23FQ36037085-C0667BE5-FDAC-49AE-AAFD-2C33038DD812Q36191786-317E68D3-9ADB-43A4-9778-814DE37F36CCQ36501562-485DDD62-6471-4A43-90E3-9C41651C4C04Q36807350-E66AF2C4-A162-41EE-9872-DE3F33E99EE0Q36809523-B4C7C621-2907-4C02-90B6-22FA31C3999FQ36813115-F32E70D6-AA63-4E8F-9C52-CAF46C53912EQ36863901-3DB2708F-2DAD-4065-A66D-CCA07669F8EAQ36939755-C93A0D50-B6CD-442D-9E59-677C83E56C2CQ37198380-CFACE2BE-6833-4737-983E-9BECDB35B2ADQ37607024-89676191-D1DC-444F-88DD-11BF66D36348Q38104654-EEE65190-A42D-43AE-9F2B-0BBEAF835DE4Q38290349-56998B8A-609D-438E-B474-A6B17B5E605DQ38789326-3B4EC5AD-ADEA-4FC8-A087-426327B40DF9Q38928777-77B3EC19-8734-418F-B88C-68EA7BE21295Q38990216-51E62837-3E38-4276-A43F-010EAA1E36DBQ39049796-2152DAFD-5982-43AF-BDBE-EA92E0150EB3Q42220275-379741FD-2659-41AF-8D9F-D00BE9416559Q45288581-FD9CAF8B-939D-4B24-89E5-9CFCDDFD820FQ45292704-DCC2316A-3A34-4EAD-8E53-1209FF0DE5BFQ45295696-72E29441-836B-4A30-9F99-EE226F01D874Q45298602-BF5402C0-6309-4BAE-9D39-C228B6DEE426
P2860
Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Conditional BDNF release under ...... delaying neuronal dysfunction.
@ast
Conditional BDNF release under ...... delaying neuronal dysfunction.
@en
type
label
Conditional BDNF release under ...... delaying neuronal dysfunction.
@ast
Conditional BDNF release under ...... delaying neuronal dysfunction.
@en
prefLabel
Conditional BDNF release under ...... delaying neuronal dysfunction.
@ast
Conditional BDNF release under ...... delaying neuronal dysfunction.
@en
P2860
P50
P356
P1476
Conditional BDNF release under ...... delaying neuronal dysfunction.
@en
P2093
Cristina Lao-Peregrin
Olga Carretón
P2860
P2888
P356
10.1186/1750-1326-6-71
P577
2011-10-10T00:00:00Z
P5875
P6179
1034627159